Study shows PrEP effective at stopping HIV infections

Gilead's drug Truvada, used in conjunction with pre-exposure prophylaxis, can reduce HIV infection rates, a study has found. That's important news for regions of the U.S. like the South, where infection rates are high and continuing to rise.

Source: bizjournals.com Health Care:Biotechnology headlines - September 20, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news